• (S)-Mephenytoin: Benchmark CYP2C19 Substrate for Organoid...

  2025-10-05

  Leverage (S)-Mephenytoin as a gold-standard mephenytoin 4-hydroxylase substrate to unlock high-fidelity CYP2C19 metabolism studies in human iPSC-derived intestinal organoids. Discover optimized workflows, troubleshooting strategies, and the translational edge gained by integrating this CYP2C19 substrate into advanced pharmacokinetic experiments.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Prote...

  2025-10-04

  Protect labile proteins and signaling events with the Protease Inhibitor Cocktail EDTA-Free, 100X in DMSO—engineered for uncompromised compatibility in phosphorylation and inflammasome studies. This robust, broad-spectrum inhibitor cocktail accelerates experimental fidelity in challenging samples like liver macrophage lysates, as exemplified in cutting-edge single-cell and proteomics workflows.

• Calpeptin and Calpain Inhibition: Beyond Pulmonary Fibros...

  2025-10-03

  Explore the advanced mechanisms and broader research applications of Calpeptin, a potent calpain inhibitor, in fibrosis and inflammation modulation. Discover how Calpeptin uniquely enables molecular dissection of the calpain signaling pathway, supporting next-generation research in pulmonary fibrosis, rheumatoid arthritis, and regulated cell death.

• 2'3'-cGAMP (sodium salt): Precision STING Agonist for Can...

  2025-10-02

  2'3'-cGAMP (sodium salt) empowers researchers to dissect and modulate the cGAS-STING pathway with unparalleled specificity, enabling transformative advances in cancer immunotherapy and antiviral innate immunity. Explore robust experimental workflows, troubleshooting strategies, and translational insights that set this gold-standard STING agonist apart from conventional cyclic dinucleotides.

• AG-490 (Tyrphostin B42): Precision Inhibition of JAK2/STA...

  2025-10-01

  Explore the transformative impact of AG-490 (Tyrphostin B42), a potent JAK2/EGFR inhibitor, on dissecting JAK-STAT and MAPK signaling pathways. This thought-leadership article weaves mechanistic insight, strategic guidance, and the latest evidence—including exosomal RNA-driven macrophage polarization in hepatocellular carcinoma (HCC)—to empower translational researchers in cancer and immunopathology.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit: Optimizin...

  2025-09-30

  The HyperScribe T7 High Yield Cy3 RNA Labeling Kit streamlines in vitro transcription RNA labeling, enabling high-yield, customizable fluorescent probe synthesis for advanced gene expression and hybridization assays. Its optimized chemistry and workflow flexibility make it the benchmark for generating highly sensitive, Cy3-labeled RNA probes—powering innovations in tumor-selective mRNA research, spatial transcriptomics, and noncoding RNA mapping.

• MLN4924: Unraveling Non-Cullin Neddylation and mTORC1 Sig...

  2025-09-29

  Explore how MLN4924, a potent NEDD8-activating enzyme inhibitor, is redefining cancer biology research by targeting non-cullin neddylation and the mTORC1 pathway. This article provides a unique, in-depth analysis of MLN4924’s mechanism, its impact on tumorigenesis, and its distinct value for anti-cancer therapeutic development.

• Eltanexor (KPT-8602): Transforming Hematological and Soli...

  2025-09-28

  Explore how Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, is advancing cancer research through targeted nuclear export inhibition. This in-depth analysis uniquely examines Eltanexor's impact on caspase signaling and Wnt/β-catenin modulation in both hematological malignancies and colorectal cancer.

• EZ Cap™ EGFP mRNA (5-moUTP): Engineering Precision for Sy...

  2025-09-27

  Explore how EZ Cap™ EGFP mRNA 5-moUTP advances in vivo mRNA delivery and translation efficiency with a Cap 1 structure and 5-moUTP modifications. This article provides a deep dive into mechanism, nanoparticle integration, and future directions for enhanced green fluorescent protein mRNA technologies.

• RSL3 as a Precision Tool: Exploiting Ferroptosis and Redo...

  2025-09-26

  Explore how RSL3, a potent glutathione peroxidase 4 inhibitor, unlocks targeted ferroptosis and iron-dependent cell death in RAS-driven cancers. This article uniquely dissects ferroptosis mechanisms, contrasts apoptotic and non-apoptotic death pathways, and offers advanced insights beyond current literature.

• SM-102 in Lipid Nanoparticles: Systems Biology and Precis...

  2025-09-25

  Explore the systems-level impact of SM-102 in lipid nanoparticles (LNPs) for mRNA delivery and vaccine development. This article uniquely integrates molecular, cellular, and predictive modeling perspectives to unveil new opportunities for precision mRNA therapeutics.

• ISRIB (trans-isomer): Advanced Strategies for Targeting t...

  2025-09-24

  Explore ISRIB (trans-isomer), a potent integrated stress response inhibitor, and its cutting-edge applications in ER stress research, liver fibrosis, and neurodegenerative models. This article reveals nuanced mechanisms and experimental strategies that set new standards for ISR pathway intervention.

• Sildenafil Citrate: Deciphering Proteoform-Specific Signa...

  2025-09-23

  Explore how Sildenafil Citrate, a selective cGMP-specific phosphodiesterase type 5 inhibitor, enables advanced research into proteoform-specific signaling, vascular smooth muscle relaxation, and apoptosis regulation. This article highlights emerging strategies for integrating proteomics and small-molecule pharmacology to elucidate PDE5-related pathways.

• S63845: Targeting MCL1 to Unlock Synergistic Apoptosis Pa...

  2025-09-22

  This article explores the mechanistic synergy between the small molecule MCL1 inhibitor S63845 and extrinsic apoptosis modulators, highlighting its role as a mitochondrial apoptotic pathway activator in cancer research. Focus is placed on recent data supporting combinatorial strategies and on practical considerations for hematological and solid tumor models.

• BMN 673 (Talazoparib): Advancing PARP1/2 Inhibitor Resear...

  2025-09-19

  Explore the latest insights into BMN 673 (Talazoparib), a potent PARP1/2 inhibitor, and its unique role in targeting DNA repair deficiencies and homologous recombination-deficient cancers. This article discusses new mechanistic findings and research applications for selective PARP inhibitors in cancer therapy.

15963 records 1/1065 page Next 12345 下5页 Last page